Kala Pharmaceuticals Inc., a biopharmaceutical company, announced the launch of INVELTYS™ (loteprednol etabonate ophthalmic suspension) 1%, the first and only twice-daily ocular corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.
INVELTYS is now in national and regional United States pharmaceutical distribution centers, and patients have access to INVELTYS through their local retail pharmacies, the company said.
The drug was approved in August 2018, and uses Kala’s AMPPLIFY Drug Delivery Technology to enhance penetration into eye tissue.
“We are excited to announce the availability of INVELTYS in the U.S., the first twice-daily topical corticosteroid with proven safety and efficacy, for the treatment of inflammation and pain following ocular surgery,” said Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals. “We are also pleased to announce that the ophthalmic specialty sales team has begun calling on and providing samples to eye care professionals.”
Kala also has filed a drug application for KPI-121 0.25%, a product candidate for the temporary relief of signs and symptoms of dry eye disease. Dry eye disease can happen at any age, but is more common in those over 50.
